{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T20:14:45Z","timestamp":1648757685266},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1990,3,1]],"date-time":"1990-03-01T00:00:00Z","timestamp":636249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blut"],"published-print":{"date-parts":[[1990,3]]},"DOI":"10.1007\/bf01720271","type":"journal-article","created":{"date-parts":[[2005,6,12]],"date-time":"2005-06-12T09:38:30Z","timestamp":1118569110000},"page":"172-176","source":"Crossref","is-referenced-by-count":1,"title":["Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas"],"prefix":"10.1007","volume":"60","author":[{"given":"F.","family":"Gherlinzoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Castoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Bellesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. L.","family":"Rossi Ferrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mangoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ascari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tabilio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F.","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Manna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Porcellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mandelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Antimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Chisesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Dini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01720271_CR1","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/1097-0142(19851001)56:7<1493::AID-CNCR2820560702>3.0.CO;2-M","volume":"56","author":"DJ Adelstein","year":"1985","unstructured":"Adelstein DJ, Lazarus HM, Hines JD, Herzig RH (1985) High-dose cytosine arabinoside in previously treated patients with poor-prognosis non-Hodgkin's lymphoma. Cancer 56: 1493\u20131496","journal-title":"Cancer"},{"key":"BF01720271_CR2","first-page":"965","volume":"69","author":"E Bajetta","year":"1985","unstructured":"Bajetta E, Buzzoni R, Viviani S (1985) Phase II study with amsacrines (m-AMSA and m-AMSA-lactate) in refractory lymphomas. Cancer Treat Rep 69: 965\u2013969","journal-title":"Cancer Treat Rep"},{"key":"BF01720271_CR3","first-page":"1","volume":"32","author":"R Bianchi","year":"1985","unstructured":"Bianchi R, Nardelli B, Allegrucci M, Fioretti MC (1985) Efficacia terapeutica del PTT-119 valutata in vivo in modelli sperimentali. G Ital Chemioter 32: 1\u201316","journal-title":"G Ital Chemioter"},{"key":"BF01720271_CR4","first-page":"26","volume":"39","author":"G Coppi","year":"1984","unstructured":"Coppi G, Berti MA, Gatti T, Mosconi P (1984) Some pharmacological studies on a new tripeptide mustard. Il Farmaco Ed Sci 39: 26","journal-title":"Il Farmaco Ed Sci"},{"key":"BF01720271_CR5","unstructured":"Coppi G, Mosconi P, Gatti MT, Berti MA (1984) Chemotherapeutical, pharmacological and toxicological properties of PTT-119, a new antitumor agent. 1st European Conference on Advances in Antitumor Agents, Milano, May 30\u2013June 1"},{"key":"BF01720271_CR6","first-page":"205","volume":"38","author":"A Barbieri De","year":"1983","unstructured":"De Barbieri A, Dall'Asta L, Comini A, Springolo V, Mosconi P, Coppi G, Bekesi G (1983) Synthesis, acute toxicity and chemotherapeutic anti-cancer activity of a new tripeptidic mustard. II Farmaco 38: 205\u2013218","journal-title":"II Farmaco"},{"key":"BF01720271_CR7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(75)91142-3","volume":"I","author":"VT DeVita Jr","year":"1975","unstructured":"DeVita VT jr, Canellos GP, Chabner BA, Schein P, Hubbard SP, Young RC (1975) Advanced diffuse histiocytic lymphoma, a potentially curable disease: results with combination chemotherapy. Lancet I: 248\u2013250","journal-title":"Lancet"},{"key":"BF01720271_CR8","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1097-0142(197810)42:4<1705::AID-CNCR2820420408>3.0.CO;2-P","volume":"42","author":"L Elias","year":"1978","unstructured":"Elias L, Portlock CS, Rosenberg SA (1978) Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 42: 1705\u20131710","journal-title":"Cancer"},{"key":"BF01720271_CR9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-98-3-304","volume":"96","author":"RI Fisher","year":"1983","unstructured":"Fisher RI, DeVita VT jr, Hubbard SM (1983) Diffuse aggressive lymphomas: increased survival after flexible sequences of Pro-MACE and MOPP chemotherapy. Ann Int Med 96: 304\u2013309","journal-title":"Ann Int Med"},{"key":"BF01720271_CR10","first-page":"C","volume":"3","author":"RI Fisher","year":"1984","unstructured":"Fisher RI, DeVita VT jr, Hubbard SM (1984) Randomized trial of ProMACE-MOPP vs. ProMACE-CytaBOM in previously untreated, advanced stage diffuse aggressive lymphomas. Proc Am Soc Clin Oncol 3: C-945","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF01720271_CR11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/07357908709011732","volume":"5","author":"C Guglielmi","year":"1987","unstructured":"Guglielmi C, Amadori S, Anselmo AP, Baroni CD, Biagini C, Cimino G, Papa G, Mandelli F (1987) Sequential chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubucin, vincristine and prednisone (F-MACHOP). Cancer Invest 5: 159\u2013169","journal-title":"Cancer Invest"},{"key":"BF01720271_CR12","doi-asserted-by":"crossref","first-page":"596","DOI":"10.7326\/0003-4819-102-5-596","volume":"102","author":"P Klimo","year":"1985","unstructured":"Klimo P, Connors JM (1985) MACOP-B Chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Int Med 102: 596\u2013602","journal-title":"Ann Int Med"},{"key":"BF01720271_CR13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.7326\/0003-4819-97-2-190","volume":"97","author":"J Laurence","year":"1982","unstructured":"Laurence J, Coltman M, Allen SL, Silver RT, Pasmantier M (1982) Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six drug COP-BLAM regimen. Ann Int Med 97: 190\u2013195","journal-title":"Ann Int Med"},{"key":"BF01720271_CR14","first-page":"195","volume":"73","author":"RM Lemoli","year":"1988","unstructured":"Lemoli RM, Visani G, Tosi P, Mazza P, Motta MR, Rizzi S, Zinzani PL, Poluzzi C, Gherlinzoni F, Tura S (1988) Effects of a new bifunctional alkylating agent (PTT-119) on in vitro growth of human cell lines and normal myeloid progenitors (CFU-GM). Haematologica 73: 195\u2013200","journal-title":"Haematologica"},{"key":"BF01720271_CR15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2141.1975.tb00911.x","volume":"31","author":"K Lennert","year":"1975","unstructured":"Lennert K, Mhori M, Stein H (1975) The histopathology of malignant lymphomas. Br J Haematol [Suppl] 31: 193\u2013203","journal-title":"Br J Haematol [Suppl]"},{"key":"BF01720271_CR16","first-page":"192","volume":"18","author":"A Martoni","year":"1986","unstructured":"Martoni A, Mazzei T, Mini E (1986) Phase I trial of a novel alkylating agent, PTT-119. Cancer Chemother Pharmacol 18: 192 (abstr)","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF01720271_CR17","unstructured":"Mini E, Mazzei T, Coronnello M, Criscuoli L, Gualtieri M, Periti P (1986) Efficacy of 3-(p-fluorophenyl)-L-alanyl-3-mbis (2-chloroethyl) amino-phenyl-L-methionine-ethoxy HCL (PTT-119) on human leukemic cell lines. 19th Int Cancer Congr, Budapest, August 21\u201327"},{"key":"BF01720271_CR18","unstructured":"Periti P, Mazzei T, Mini E (1986) Phase I clinical trial of a new alkylating agent, PTT-119. 19th Int Cancer Congress, Budapest, August 21\u201327"},{"key":"BF01720271_CR19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V49.3.325.325","volume":"49","author":"V Rodriguez","year":"1977","unstructured":"Rodriguez V, Cabanillas F, Burgess MA (1977) Combination chemotherapy (CHOP-Bleo) in advanced non-Hodgkin's malignant lymphomas. Blood 49: 325\u2013339","journal-title":"Blood"},{"key":"BF01720271_CR20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/0003-4819-85-4-417","volume":"85","author":"PS Schein","year":"1976","unstructured":"Schein PS, DeVita VT jr, Hubbard S (1976) Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Int Med 85: 417\u2013422","journal-title":"Ann Int Med"},{"key":"BF01720271_CR21","first-page":"C","volume":"4","author":"M Schipp","year":"1985","unstructured":"Schipp M, Klatt M, Harrington D (1985) M-BACOD and m-BACOD in the treatment of unfavourable prognosis lymphoma: analysis of prognostic variables. Proc Am Soc Oncol 4: C-799","journal-title":"Proc Am Soc Oncol"},{"key":"BF01720271_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1200\/JCO.1983.1.2.91","volume":"1","author":"AT Skarin","year":"1983","unstructured":"Skarin AT, Canellos GP, Rosenthal DS (1983) Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1: 91\u201398","journal-title":"J Clin Oncol"},{"key":"BF01720271_CR23","first-page":"302","volume":"7","author":"C Sweet","year":"1980","unstructured":"Sweet C, Golomb HM (1980) The treatment of histiocytic lymphoma. Semin Oncol 7: 302\u2013309","journal-title":"Semin Oncol"},{"key":"BF01720271_CR24","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","volume":"49","author":"The Non Hodgkin's Lymphoma Pathologic Classification Project","year":"1982","unstructured":"The Non Hodgkin's Lymphoma Pathologic Classification Project (1982) National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for clinical usage. Cancer 49: 2112\u20132135","journal-title":"Cancer"},{"key":"BF01720271_CR25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF00273532","volume":"23","author":"S Tura","year":"1989","unstructured":"Tura S, Mazza P, Gherlinzoni F, Zinzani PL, Poletti G, Visani G, Lemoli RM, Cavo M, Galieni P, Tassi C, Zanchini R (1989) Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non Hodgkin's lymphomas. Cancer Chem Pharmacol 23: 123\u2013125","journal-title":"Cancer Chem Pharmacol"},{"key":"BF01720271_CR26","volume-title":"WHO Offset Publication 48","author":"WHO: WHO Handbook for reporting results of cancer treatment","year":"1979","unstructured":"WHO: WHO Handbook for reporting results of cancer treatment (1979) WHO Offset Publication 48, WHO, Geneve"},{"key":"BF01720271_CR27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/BF00254592","volume":"12","author":"MJ Yagi","year":"1984","unstructured":"Yagi MJ, Bekesi JG, Daniel MD, Holland JF, De Barbieri A (1984) Increased canceridal activity of PTT-119, a new synthetic bis-(2-chlorethyl) amino-L-phenylalanine derivative with carrier amino acids. In vitro bioassays. Cancer Chemother Pharmacol 12: 70\u201376","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF01720271_CR28","first-page":"336","volume":"26","author":"MJ Yagi","year":"1985","unstructured":"Yagi MJ, Chin SE, Holland JF, Bekesi JG (1985) Effectiveness of PTT-119 against susceptible and drug-resistant tumor cells. Proc Am Soc Cancer Res 26: 336","journal-title":"Proc Am Soc Cancer Res"},{"key":"BF01720271_CR29","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/0006-2952(85)90793-2","volume":"34","author":"MJ Yagi","year":"1985","unstructured":"Yagi MJ, Chin SE, Scanlon KJ, Holland JF, Bekesi JG (1985) PTT-119, p-F-M-bis-(2-chloroethyl) amino-L-Phe-Met-Ethoxy HCL, a new chemotherapeutic agent active against drug-resistant tumor cell lines. Biochem Pharmacol 34: 2347\u20132354","journal-title":"Biochem Pharmacol"},{"key":"BF01720271_CR30","first-page":"77","volume":"12","author":"MJ Yagi","year":"1984","unstructured":"Yagi MJ, Zanjani M, Holland JF, Bekesi JG (1984) Increased canceridal activity of PTT-119, a new synthetic bis-(2-chloroethyl) amino-L-phenylalanine derivative with carrier amino acids. In vivo bioassay. Cancer Chemother Pharmacol 12: 77\u201382","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Blut"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01720271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01720271\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01720271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T17:42:47Z","timestamp":1586281367000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01720271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1990,3]]}},"alternative-id":["BF01720271"],"URL":"https:\/\/doi.org\/10.1007\/bf01720271","relation":{},"ISSN":["0006-5242","1432-0584"],"issn-type":[{"value":"0006-5242","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,3]]}}}